Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Метастатическое поражение легких при остеосаркоме

https://doi.org/10.24287/1726-1708-2019-18-4-127-135

Полный текст:

Аннотация

Остеосаркома относится к наиболее часто встречающимся злокачественным опухолям костей у детей и подростков. До начала применения полихимиотерапии смертность при метастатической болезни при остеосаркоме составляла более 90%. Несмотря на постоянное развитие протоколов терапии и наблюдения, в процессе лечения у 30–40% пациентов заболевание носит рецидивирующий характер, при этом более чем у 80% из них выявляют метастазы в легких. В данном обзоре рассмотрены проблемы диагностики метастатического поражения легких и современные подходы к методам обнаружения и маркировки метастатических очагов легких малых размеров. Дополнительная опция в лечении метастазов легких, недоступных для выявления и хирургической резекции, – интраоперационная изолированная химиоперфузия легкого. Рассмотрены также хирургические подходы к изолированной перфузии легких.

Об авторах

И. В. Жилкин
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия

Контактная информация: Жилкин Илья Владимирович, врач-педиатр, НМИЦ детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России.

Адрес: 117997, Москва, ГСП-7, ул. Саморы Машела, 1


Д. Г. Ахаладзе
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Д. В. Литвинов
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Н. Г. Ускова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


М. В. Тихонова
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Н. С. Грачев
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


А. И. Карачунский
ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
Москва


Список литературы

1. Isakoff M.S., Bielack S.S., Meltzer P., Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol 2015 Sep 20; 33 (27): 3029–35.

2. Stiller C.A., Bielack S.S., Jundt G., Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006 Sep; 42 (13): 2124–35.

3. Ries L.А.G., Smith M.A., Gurney J.G., Linet M., Tamra T., Young J.L., et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995.

4. Ritter J., Bielack S.S. Osteosarcoma. Ann Oncol 2010 Oct; 21 Suppl 7: vii320–325.

5. Szendroi M., Pápai Z., Koós R., Illés T. Limb-saving surgery, survival, and prognostic factors for osteosarcoma: the Hungarian experience. J Surg Oncol 2000 Feb; 73 (2): 87–94.

6. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., Helmke K., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002 Feb 1; 20 (3): 776–90.

7. Kandioler D., Krömer E., Tüchler H., End A., Müller M.R., Wolner E., et al. Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998 Apr; 65 (4): 909–12.

8. Meyers P.A., Heller G., Healey J.H., Huvos A., Applewhite A., Sun M., et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993 Mar; 11 (3): 449–53.

9. Marina N.M., Smeland S., Bielack S.S., Bernstein M., Jovic G., Krailo M.D., at al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncology 2016; 17 (10): 1396–408.

10. Kempf-Bielack B., Bielack S.S., Jürgens H., Branscheid D., Berdel W.E., Exner G.U., et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005 Jan 20; 23 (3): 559–68.

11. Aljubran A.H., Griffin A., Pintilie M., Blackstein M. Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 2009 Jun; 20 (6): 1136–41.

12. Gelderblom H., Jinks R.C., Sydes M., Bramwell V.H.C., van Glabbeke M., Grimer R.J., et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011 Apr; 47 (6): 895–902.

13. Bacci G., Briccoli A., Ferrari S., Longhi A., Mercuri M., Capanna R., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 2001 Nov; 37 (16): 2030–9.

14. Petrilli A.S., de Camargo B., Filho V.O., Bruniera P., Brunetto A.L., Jesus-Garcia R., et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. J Clin Oncol 2006 Mar 1; 24(7): 1161–8.

15. Kager L., Zoubek A., Pötschger U., Kastner U., Flege S., Kempf-Bielack B., et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003 May 15; 21 (10): 2011–8.

16. Mialou V., Philip T., Kalifa C., Perol D., Gentet J.-C., Marec-Berard P., et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer 2005 Sep 1; 104 (5): 1100–9.

17. Briccoli A., Rocca M., Salone M., Guzzardella G.A., Balladelli A., Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol 2010 Dec; 19 (4): 193–9.

18. Bacci G., Rocca M., Salone M., Balladelli A., Ferrari S., Palmerini E., et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008 Nov 1; 98 (6): 415–20.

19. Harris M.B., Cantor A.B., Goorin A.M., Shochat S.J., Ayala A.G., Ferguson W.S., et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995 Feb; 24 (2): 87–92.

20. Hawkins D.S., Arndt C.A.S. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.

21. Cancer 2003 Dec 1; 98 (11): 2447–56.

22. Daw N.C., Chou A.J., Jaffe N., Rao B.N., Billups C.A., Rodriguez-Galindo C., et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br J Cancer 2015 Jan 20; 112 (2): 278–82.

23. Briccoli A., Rocca M., Salone M., Bacci G., Ferrari S., Balladelli A., et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 2005; 104 (8): 1721–5.

24. Bielack S.S., Kempf-Bielack B., Branscheid D., Carrle D., Friedel G., Helmke K., et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009 Feb 1; 27 (4): 557–65.

25. Temeck B.K., Wexler L.H., Steinberg S.M., McClure L.L., Horowitz M., Pass H.I. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 1995 Jun; 59 (6): 1385–9; discussion 1390.

26. Iwata S., Yonemoto T., Iizasa T., Niibe Y., Kamoda H., Ishii T. Oligo-Recurrence of Osteosarcoma Patients: Treatment Strategies for Pulmonary Metastases. Ann Surg Oncol 2015 Dec; 22 Suppl 3: S1332–8.

27. Salah S., Fayoumi S., Alibraheem A., Massad E., Abdel Jalil R., Yaser S., et al. The influence of pulmonary metastasectomy on survival in osteosarcoma and soft-tissue sarcomas: a retrospective analysis of survival outcomes, hospitalizations and requirements of home oxygen therapy. Interact Cardiovasc Thorac Surg 2013 Aug; 17 (2): 296–302.

28. Denbo J.W., Zhu L., Srivastava D., Stokes D.C., Srinivasan S., Hudson M.M., et al. Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. J Am Coll Surg 2014 Aug; 219 (2): 265–71.

29. Carter S.R., Grimer R.J., Sneath R.S., Matthews H.R. Results of thoracotomy in osteogenic sarcoma with pulmonary metastases. Thorax 1991 Oct; 46 (10): 727–31.

30. Van Geel A.N., Pastorino U., Jauch K.W., Judson I.R., Van Coevorden F., Buesa J.M., at al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer: Interdisciplinary International Journal of the American Cancer Society 1996; 77 (4): 675–82.

31. Harting M.T., Blakely M.L., Jaffe N., Cox C.S., Hayes-Jordan A., Benjamin R.S., et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 2006 Jan; 41 (1): 194–9.

32. Fernandez-Pineda I., Daw N.C., McCarville B., Emanus L.J., Rao B.N., Davidoff A.M., et al. Patients with osteosarcoma with a single pulmonary nodule on computed tomography: a singleinstitution experience. J Pediatr Surg 2012 Jun; 47 (6): 1250–4.

33. Xiao X., Wang W., Wang Z. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma. Paediatr Drugs 2014 Dec; 16 (6): 503–12.

34. Yamamoto N., Tsuchiya H. Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going? Expert Opin Pharmacother 2013 Nov; 14 (16): 2183–93.

35. Ferrari S., Briccoli A., Mercuri M., Bertoni F., Picci P., Tienghi A., et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003 Feb 15; 21 (4): 710–5.

36. Crompton B.D., Goldsby R.E., Weinberg V.K., Feren R., O’Donnell R.J., Ablin A.R. Survival after recurrence of osteosarcoma: a 20-year experience at a single institution. Pediatr Blood Cancer 2006 Sep; 47 (3): 255–9.

37. Leary S.E.S., Wozniak A.W., Billups C.A., Wu.J., McPherson V., Neel M.D., et al. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer 2013 Jul 15; 119 (14): 2645–53.

38. Tabone M.D., Kalifa C., Rodary C., Raquin M., Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. Journal of Clinical Oncology 1994; 12 (12): 2614–20.

39. Seo J.B., Im J.G., Goo J.M., Chung M.J., Kim M.Y. Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics 2001; 21 (2): 403–17.

40. Iagaru A., Chawla S., Menendez L., Conti P.S. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nuclear Medicine Communications 2006 Oct; 27 (10): 795.

41. Franzius C., Daldrup-Link H.E., Sciuk J., Rummeny E.J., Bielack S., Jürgens H., et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001 Apr; 12 (4): 479–86.

42. Reinhardt M.J., Wiethoelter N., Matthies A., Joe A.Y., Strunk H., Jaeger U., at al. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images. European journal of nuclear medicine and molecular imaging 2006; 33 (2): 134–9.

43. Liu F., Zhang Q., Zhu D., Li Z., Li J., Wang B., et al. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015 Sep; 94 (36): e1462.

44. Ferguson W.S., Goorin A.M. Current treatment of osteosarcoma. Cancer Invest 2001; 19 (3): 292–315.

45. Jeffree G.M., Price C.H., Sissons H.A. The metastatic patterns of osteosarcoma. Br J Cancer 1975 Jul; 32 (1): 87–107.

46. Meyer J.S., Nadel H.R., Marina N., Womer R.B., Brown K.L.B., Eary J.F., et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008 Aug; 51 (2): 163–70.

47. Kayton M.L., Huvos A.G., Casher J., Abramson S.J., Rosen N.S., Wexler L.H., et al. Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. J Pediatr Surg 2006 Jan; 41 (1): 200–6; discussion 200–6.

48. McCormack P.M., Bains M.S., Begg C.B., Burt M.E., Downey R.J., Panicek D.M., et al. Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg 1996 Jul; 62 (1): 213–6; discussion 216–7.

49. Yim A.P., Lin J., Chan A.T., Li C.K., Ho J.K. Video-assisted thoracoscopic wedge resections of pulmonary metastatic osteosarcoma: should it be performed? Aust N Z J Surg 1995 Oct; 65 (10): 737–9.

50. Fuchs J., Seitz G., Handgretinger R., Schäfer J., Warmann S.W. Surgical treatment of lung metastases in patients with embryonal pediatric solid tumors: an update. Seminars in Pediatric Surgery 2012 Feb 1; 21 (1): 79–87.

51. Picci P., Vanel D., Briccoli A., Talle K., Haakenaasen U., Malaguti C., et al. Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 2001 Nov; 12 (11): 1601–4.

52. Wicky S., Dusmet M., Doenz F., Ris H.B., Schnyder P., Portier F. Computed tomography–guided localization of small lung nodules before video-assisted resection: Experience with an efficient hook-wire system. The Journal of Thoracic and Cardiovascular Surgery 2002 Aug 1; 124 (2): 401–3.

53. Dendo S., Kanazawa S., Ando A., Hyodo T., Kouno Y., Yasui K., et al. Preoperative Localization of Small Pulmonary Lesions with a Short Hook Wire and Suture System: Experience with 168 Procedures. Radiology 2002 Nov 1; 225 (2): 511–8.

54. Plunkett M.B., Peterson M.S., Landreneau R.J., Ferson P.F., Posner M.C. Peripheral pulmonary nodules: preoperative percutaneous needle localization with CT guidance. Radiology 1992 Oct 1; 185 (1): 274–6.

55. Sortini D., Feo C.V., Carcoforo P., Carrella G., Pozza E., Liboni A., et al. Thoracoscopic Localization Techniques for Patients With Solitary Pulmonary Nodule and History of Malignancy. The Annals of Thoracic Surgery 2005 Jan 1; 79 (1): 258–62.

56. Shennib H., Bret P. Intraoperative transthoracic ultrasonographic localization of occult lung lesions. The Annals of Thoracic Surgery 1993 Mar 1; 55 (3): 767–9.

57. Asano F., Shindoh J., Shigemitsu K., Miya K., Abe T., Horiba M., et al. Ultrathin Bronchoscopic Barium Marking With Virtual Bronchoscopic Navigation for Fluoroscopy-Assisted Thoracoscopic Surgery. Chest 2004 Nov 1; 126 (5): 1687–93.

58. Okumura T., Kondo H., Suzuki K., Asamura H., Kobayashi T., Kaneko M., et al. Fluoroscopy-assisted thoracoscopic surgery after computed tomography-guided bronchoscopic barium marking. The Annals of Thoracic Surgery 2001 Feb 1; 71 (2): 439–42.

59. Endo M., Kotani Y., Satouchi M., Takada Y., Sakamoto T., Tsubota N., et al. CT Fluoroscopy-Guided Bronchoscopic Dye Marking for Resection of Small Peripheral Pulmonary Nodules. Chest 2004 May 1; 125 (5): 1747–52.

60. Kerrigan D.C., Spence P.A., Crittenden M.D., Tripp M.D. Methylene blue guidance for simplified resection of a lung lesion. The Annals of Thoracic Surgery 1992 Jan 1; 53 (1): 163–4.

61. Nomori H., Horio H. Colored collagen is a long-lasting point marker for small pulmonary nodules in thoracoscopic operations. The Annals of Thoracic Surgery 1996 Apr 1; 61 (4): 1070–3.

62. Moon S.-W., Wang Y.-P., Jo K.-H., Kwack M.-S., Kim S.-W., Kwon O.-K., et al. Fluoroscopy-aided thoracoscopic resection of pulmonary nodule localized with contrast media. The Annals of Thoracic Surgery 1999 Nov 1; 68 (5): 1815–20.

63. Nomori H., Horio H., Naruke T., Suemasu K. Fluoroscopy-assisted thoracoscopic resection of lung nodules marked with lipiodol. The Annals of Thoracic Surgery 2002 Jul 1; 74 (1): 170–3.

64. Watanabe K., Nomori H., Ohtsuka T., Kaji M., Naruke T., Suemasu K. Usefulness and complications of computed tomography-guided lipiodol marking for fluoroscopy-assisted thoracoscopic resection of small pulmonary nodules: Experience with 174 nodules. The Journal of Thoracic and Cardiovascular Surgery 2006 Aug 1; 132 (2): 320–4.

65. Tsuchida M., Yamato Y., Aoki T., Watanabe T., Koizumi N., Emura I., et al. CT-Gui-ded Agar Marking for Localization of Nonpalpable Peripheral Pulmonary Lesions. Chest 1999 Jul 1; 116 (1): 139–43.

66. Iwasaki Y., Nagata K., Yuba T., Hosogi S., Kohno K., Ohsugi S., at al. Fluoroscopy-guided barium marking for localizing small pulmonary lesions before video-assisted thoracic surgery. Respiratory medicine 2005; 99 (3); 285–9.

67. Gaffke G., Stroszczynski C., Rau B., Liebeskind U., Hünerbein M., Bayraktar S., et al. [CT-guided resection of pulmonary metastases]. Rofo 2005 Jun; 177 (6): 877–83.

68. Kamiyoshihara M., Sakata K., Ishikawa S., Morishita Y. Cerebral arterial air embolism following CT-guided lung needle marking: report of a case. Journal of Cardiovascular Surgery 2001; 42 (5): 699.

69. Horan T.A., Pinheiro P.M., Araújo L.M., Santiago F.F., Rodrigues M.R. Massive gas embolism during pulmonary nodule hook wire localization. The Annals of thoracic surgery 2002; 73 (5): 1647–9.

70. Sakiyama S., Kondo K., Matsuoka H., Yoshida M., Miyoshi T., Yoshida S., et al. Fatal air embolism during computed tomography–guided pulmonary marking with a hook-type marker. The Journal of Thoracic and Cardiovascular Surgery 2003 Oct 1; 126 (4): 1207–9.

71. Sato K., Miyauchi K., Shikata F., Murakami T., Yoshioka S., Kawachi K. Arterial air embolism during percutaneous pulmonary marking under computed tomography guidance. Jpn J Thorac Caridovasc Surg 2005 Jul 1; 53 (7): 404–6.

72. Creech O., Krementz E., Ryan R., Winblad J. Chemotherapy of Cancer. Annals of Surgery 1958 Oct 1; 148 (4): 616–32.

73. Ranney D.F. Drug targeting to the lungs. Biochemical Pharmacology 1986 Apr 1; 35 (7): 1063–9.

74. Nawata S., Abecasis N., Ross H.M., Abolhoda A., Cheng H., Sachar K.S., et al. Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. The Journal of Thoracic and Cardiovascular Surgery 1996 Dec 1; 112 (6): 1542–8.

75. Hendriks J.M.H., Van Schil P.E.Y. Isolated lung perfusion for the treatment of pulmonary metastases. Surgical Oncology 1998 Jul 1; 7 (1): 59–63.

76. Левченко Е.В., Гумбатова Э.Д., Кулева С.А., Сенчик К.Ю., Мамонтов О.Ю., Калинин П.С. и др. Изолированная химиоперфузия легкого и плевры как метод лечения у детей с распространенными формами солидных опухолей костей. Российский журнал детской гематологии и онкологии 2019; 1. https://cyberleninka.ru/article/n/izolirovannaya-himioperfuziya-legkogoiplevry-kak-metod-lecheniya-u-detey-s-rasprostranennymi-formami-solidnyh-opuholey-kostey

77. Гумбатова Э.Д. Метастатическое поражение легких у детей с солидными опухолями: исторический экскурс.оссийский журнал детской гематологии и онкологии 2019; 1. https://cyberleninka.ru/article/n/izolirovannaya-himioperfuziya-legkogo-i-plevry-kak-metod-lecheniya-u-detey-s-rasprostranennymi-formami-solidnyh-opuholey-kostey

78. Левченко Е.В., Калинин П.С., Сенчик К.Ю., Чжан Вэнь, Ван Тин, Мамонтов О.Ю. и др. Обоснование модели расчета индивидуальной дозы цитостатиков с использованием КТ-волюметрии для изолированной химиоперфузии легкого с метастазэктомией. Вопросы онкологии 2018; 64 (3): 319–23.

79. Hendriks J.M.H., Grootenboers M.J.J.H., Schramel F.M.N.H., van Boven W.J., Stockman B., Seldenrijk C.A., et al. Isolated Lung Perfusion With Melphalan for Resectable Lung Metastases: A Phase I Clinical Trial. The Annals of Thoracic Surgery 2004 Dec 1; 78 (6): 1919–27.

80. Grootenboers M.J.J.H., Schramel F.M.N.H., van Boven W.J., van Putte B.P., Hendriks J.M.H., Van Schil P.E.Y. Re-Evaluation of Toxicity and Long-Term Follow-Up of Isolated Lung Perfusion With Melphalan in Patients With Resectable Pulmonary Metastases: A Phase I and Extension Trial. Annals of Thoracic Surgery 2007; 83 (3): 1235–6.

81. Den Hengst W.A., Van Putte B.P., Hendriks J.M.H., Stockman B., van Boven W.-J.P., Weyler J., et al. Long-term survival of a phase I clinical trial of isolated lung perfusion with melphalan for resectable lung metastases. European Journal of Cardio-thoracic Surgery 2010; 38 (5): 621–7.

82. den Hengst W.A., Hendriks J.M.H., Balduyck B., Rodrigus I., Vermorken J.B., Lardon F., et al. Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases. Journal of Thoracic Oncology 2014 Oct 1; 9 (10): 1547–53.

83. Kümmerle A., Krueger T., Dusmet M., Vallet C., Pan Y., Ris H.B., et al. A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. Journal of Pharmaceutical and Biomedical Analysis 2003 Oct 15; 33 (3): 475–94.

84. Schrump D.S., Zhai S., Nguyen D.M., Weiser T.S., Fisher B.A., Terrill R.E., et al. Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques. The Journal of Thoracic and Cardiovascular Surgery 2002 Apr 1; 123 (4): 686–94.

85. Schröder C., Fisher S., Pieck A.C., Müller A., Jaehde U., Kirchner H., et al. Technique and results of hyperthermic (41 °C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis. European Journal of Cardiothoracic Surgery 2002; 22 (1): 41–6.

86. Burt M.E., Liu D., Abolhoda A., Ross H.M., Kaneda Y., Jara E., et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial. The Annals of Thoracic Surgery 2000 May 1; 69 (5): 1542–9.

87. Ratto G.B., Toma S., Civalleri D., Passerone G.C., Esposito M., Zaccheo D., et al. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas. The Journal of Thoracic and Cardiovascular Surgery 1996 Sep 1; 112 (3): 614–22.

88. Pass H.I., Mew D.J.Y., Kranda K.C., Temeck B.K., Donington J.S., Rosenberg S.A. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. The Annals of Thoracic Surgery 1996 Jun 1; 61 (6): 1609–17.

89. Hendriks J.M.H., Van Putte B.P., Grootenboers M., Van Boven W.J., Schramel F., Van Schil P.E.Y. Isolated Lung Perfusion for Pulmonary Metastases. Thoracic Surgery Clinics 2006 May 1; 16 (2): 185–98.

90. Furrer M., Lardinois D., Thormann W., Altermatt H.-J., Betticher D., Triller J., et al. Cytostatic Lung Perfusion by Use of an Endovascular Blood Flow Occlusion Technique. The Annals of Thoracic Surgery 1998 Jun 1; 65 (6): 1523–8.

91. Van Putte B.P., Hendriks J.M., Romijn S., Pauwels B., De Boeck G., Guetens G., еt al. Pharmacokinetics after pulmonary artery perfusion with gemcitabine. The Annals of thoracic surgery 2003; 76 (4): 1036–40.

92. Kümmerle A., Krueger T., Dusmet M., Vallet C., Pan Y., Ris H.B., et al. A validated assay for measuring doxorubicin in biological fluids and tissues in an isolated lung perfusion model: matrix effect and heparin interference strongly influence doxorubicin measurements. Journal of Pharmaceutical and Biomedical Analysis 2003 Oct 15; 33 (3): 475–94.

93. Jinbo M., Ueda K., Kaneda Y., Sudo M., Li T.-S., Hamano K. Video-assisted transcatheter lung perfusion regional chemotherapy. Eur J Cardiothorac Surg 2005 Jun 1; 27 (6): 1079–82.

94. Franke U.F.W., Wittwer T., Kaluza M., Albert M., Becker V., Roskos M., et al. Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue. Eur J Cardiothorac Surg 2004 Oct 1; 26 (4): 800–6.

95. Franke U.F.W., Wittwer T., Lessel M., Liebing K., Albert M., Becker V., et al. Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: I. Influence of perfusion pressure and hyperthermia on functional and morphological lung integrity. Eur J Cardiothorac Surg 2004 Oct 1; 26 (4): 792–9.

96. Vogl T.J., Lehnert T., Zangos S., Eichler K., Hammerstingl R., Korkusuz H., et al. Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases. Eur Radiol 2008 Nov 1; 18 (11): 2449–55.

97. Vogl T.J., Wetter A., Lindemayr S., Zangos S. Treatment of Unresectable Lung Metastases with Transpulmonary Chemoembolization: Preliminary Experience. Radiology 2005 Mar 1; 234 (3): 917–22.


Для цитирования:


Жилкин И.В., Ахаладзе Д.Г., Литвинов Д.В., Ускова Н.Г., Тихонова М.В., Грачев Н.С., Карачунский А.И. Метастатическое поражение легких при остеосаркоме. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019;18(4):127-135. https://doi.org/10.24287/1726-1708-2019-18-4-127-135

For citation:


Zhilkin I.V., Akhaladze D.G., Litvinov D.V., Uskova N.G., Tihonova M.V., Grachev N.S., Karachunskiy A.I. Osteosarcoma with lung metastases. Pediatric Hematology/Oncology and Immunopathology. 2019;18(4):127-135. (In Russ.) https://doi.org/10.24287/1726-1708-2019-18-4-127-135

Просмотров: 212


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)